ClinicalTrials.gg
CompletedNCT05929079TRIUMPH-2Updated Jul 30, 2026

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

A Phase 3 interventional study of Retatrutide and Placebo in Type 2 Diabetes, Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 98 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing retatrutide in Diabetes Mellitus, Type 2 — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Diabetes Mellitus, Type 2.

Enrollment
3rd of 10
1,152 · median 301
Started
2023
with 1 other
Phase 3
5 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
10 of 10
Eli Lilly and Company

Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

03

Conditions studied

  • Type 2 Diabetes
  • Obesity
  • Overweight
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) greater than or equal to 27.0 kilogram/square meter (kg/m ²)
  • Have Type 2 Diabetes (T2D)
  • Are on stable treatment for T2D for at least 90 days
  • Have a history of at least one unsuccessful dietary effort to lose body weight.

GSA2 Inclusion Criteria

  • Previously diagnosed with OSA
  • Have AHI ≥15 on polysomnography at screening (definition of moderate-to-severe OSA)
  • For participants not on positive airway pressure (PAP) therapy: unable or unwilling to use PAP therapy and have not used PAP for at least 4 weeks prior to screening.
  • If on PAP therapy, have been on PAP therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using PAP therapy for approximately 7 days prior to each of the sleep study (PSG) visits.

Exclusion criteria

Exclusion Criteria:

  • Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days.
  • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  • Have a prior or planned surgical treatment for obesity.
  • Have Type 1 diabetes
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had pancreatitis

GSA2 Exclusion Criteria

  • Use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening.
  • Use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening.
  • Use a dental appliance or other device to treat OSA other than PAP therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,152 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose 1

    Participants will receive retatrutide subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 2

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 3

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 80

  2. Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset

    Time frame: Baseline, Week 80

Secondary outcomes

  1. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 80

  2. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 80

  3. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 80

  4. Change from Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 80

  5. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 80

  6. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 80

  7. Change from Baseline in Hemoglobin (A1c) HbA1c %

    Time frame: Baseline, Week 80

  8. Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

    Time frame: Baseline, Week 80

  9. Change from Baseline in Fasting Glucose

    Time frame: Baseline, Week 80

  10. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

    AUC is presented as a single average measure of AUC across the study duration.

    Time frame: Baseline through Week 80

  11. Percent Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset

    Time frame: Baseline, Week 80

  12. A Hierarchical Combination of Functional Outcomes of Sleep Questionnaire (FOSQ) 10 score, FOSQ Vigilance Domain Score, and FOSQ Activity Level Domain Score for GSA2 Subset

    A hierarchical combination of change from baseline in the FOSQ 10 score, FOSQ Vigilance Domain Score, and FOSQ Activity Level Domain Score will be assessed by the win ratio. The reported unit will be the total "wins" for each treatment group from performing a hierarchical comparison of the component.

    Time frame: Baseline to Week 80

  13. Percentage of Participants with ≥50% AHI Reduction from Baseline for GSA2 Subset

    Time frame: Baseline to Week 80

  14. Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset

    Time frame: Week 80

07

Study locations

98 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Core Healthcare Group
    Cerritos, California 90703, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Teradan Clinical Trials, LLC
    Brandon, Florida 33511, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Clinical Site Partners LLC, dba Flourish Research
    Miami, Florida 33186, United States
  • Quantum Clinical Trials
    Miami Beach, Florida 33140, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • Centricity Research Rincon Pulmonology
    Rincon, Georgia 31406, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Mid Hudson Medical Research
    New Windsor, New York 12553, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Intrepid Research
    Cincinnati, Ohio 45245, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Tribe Clinical Research - Spartanburg
    Spartanburg, South Carolina 29301, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, Buenos Aires F.D. 1405, Argentina
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D. C1120AAC, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
  • Centro de Salud e Investigaciones Médicas
    Santa Rosa, La Pampa Province 6300, Argentina
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • Woolcock Institute of Medical Research
    Macquarie Park, New South Wales 2113, Australia
  • The AIM Centre / Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
  • Core Research Group
    Brisbane, Queensland 4064, Australia
  • Nightingale Research
    Adelaide, South Australia 5000, Australia
  • Flinders University
    Bedford Park, South Australia 5042, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Oaklands Park, South Australia 5046, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Austin Health - Repatriation Hospital
    Heidelberg West, Victoria 3081, Australia
  • Advara HeartCare Joondalup
    Joondalup, Western Australia 6027, Australia
  • CPQuali Pesquisa Clínica
    São Paulo, São Paulo 01228-000, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria
    São Paulo, São Paulo 01236030, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, São Paulo 04266-010, Brazil
  • All India Institute of Medical Sciences
    Raipur, Chhattisgarh 492099, India
  • V.S. General Hospital
    Ahmedabad, Gujarat 380006, India
  • Avron Hospitals
    Ahmedabad, Gujarat 380013, India
  • Zydus Hospitals & Healthcare Research Pvt.Ltd.
    Ahmedabad, Gujarat 380054, India
  • Life Care Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • Sushruta Multispeciality Hospital & Research Centre
    Hubli, Karnataka 580021, India
  • Mysore Medical College
    Mysore, Karnataka 570001, India
  • CARE CHL-Hospitals
    Indore, Madhya Pradesh 452008, India
  • Sawai Man Singh Medical College Hospital (SMS Hospital)
    Jaipur, Rajasthan 302004, India
  • Madras Diabetes Research Foundation
    Chennai, Tamil Nadu 600086, India
  • Christian Medical College Vellore
    Vellore, Tamil Nadu 632004, India
  • Care Hospitals Hyderabad- Banjara Hills
    Hyderabad, Telangana 500034, India
  • Diabetes Research Center
    Hyderabad, Telangana 500082, India
  • Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital
    Kolkata, West Bengal 700020, India
  • Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos
    Chihuahua City, Chihuahua 31110, Mexico
  • Centro de Investigacion en Artritis y Osteoporosis SC
    Mexicali, Estado de Baja California 21200, Mexico
  • Diseno y Planeacion en Investigacion Medica
    Guadalajara, Jalisco 44130, Mexico
  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario
    Guadalajara, Jalisco 44670, Mexico
  • Unidad de Investigación Clínica y Atención Médica HEPA
    Guadalajara, Jalisco 44670, Mexico
  • RM Pharma Specialists
    Mexico City, Mexico City 03100, Mexico
  • Clinica Omega
    Mexico City, Mexico City 06700, Mexico
  • Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
    Mexico City, Mexico City 11650, Mexico
  • Cardiolink Clin Trials
    Monterrey, Nuevo León 64060, Mexico
  • Unidad biomedica avanzada monterrey
    Monterrey, Nuevo León 64460, Mexico
  • FAICIC S. de R.L. de C.V.
    Veracruz, Veracruz 91900, Mexico
  • Arké SMO S.A de C.V
    Veracruz, Veracruz 91910, Mexico
  • CMI Dr.Pletea Noemi SRL
    Bacau, Bacău 600154, Romania
  • Diabdana
    Oradea, Bihor County 410147, Romania
  • Geea Medical Easy Diet
    Bucharest, Bucharest 010627, Romania
  • Centrul Medical NutriLife
    Bucharest, Bucharest 013764, Romania
  • Gama Diamed
    Mangalia, Constanța County 905500, Romania
  • Centrul Medical Mediab
    Târgu Mureş, Mureș County 540142, Romania
  • Centro Periférico de Especialidades Bola Azul
    Almería, Almería 04009, Spain
  • H.R.U Málaga - Hospital Civil
    Málaga, Andalusia 29009, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Andalusia 29010, Spain
  • Complejo Asistencial Universitario de León - Hospital de León
    León, Castille and León 24071, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad de 28034, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, Sevilla 41013, Spain
  • Vithas Hospital Sevilla
    Seville, Sevilla 41950, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: a are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2026, 35 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 35 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 3, 2023
StartActual
Jul 11, 2023
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929079
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Jul 11, 2023
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Jul 30, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion